来自食物的生物活性,在类风湿性关节炎中强化治疗干预
Chunhong Liu1, Zheng Yan1, Xiaohai Zhang1
1Second People's Hospital of Wuhu City, 241001, Anhui, China.
Heliyon
|May 23, 2024
概括
食品衍生 (FDPs) 显示出对治疗类风湿性关节炎 (RA) 的承诺,其副作用比传统治疗方法少. 本综述探讨了炎症,RA,以及FDPs在RA管理中的治疗潜力.
科学领域:
- 免疫学和风湿病学
- 生物化学和分子生物学
背景情况:
- 风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,影响关节,预计到2030年全球新发病人数将达到150万.
- 传统和替代性RA治疗方法存在,但往往会带来严重的副作用,如胃肠道问题,肝损伤和出血风险.
研究的目的:
- 审查炎症的概念,其类型,以及类风湿性关节炎的病变发生.
- 引入食品衍生 (FDPs) 作为一种潜在的治疗策略来治疗RA.
- 为了突出FDPs相对于传统的RA疗法的优势,因为它们的副作用最小.
主要方法:
- 关于炎症,RA病原和病理生理学的文献综述.
- 探索目前对RA的常规治疗选择.
- 识别和分析针对RA治疗的食品衍生 (FDPs) 的研究.
主要成果:
- 炎症,特别是RA中出现的慢性炎症,是一个复杂的过程.
- 传统的RA治疗有各种不良影响.
- 来自植物和动物来源的食品衍生 (FDPs) 显示出RA管理的潜力,具有有利的副作用概况.
结论:
- 食物衍生的 (FDPs) 为 RA 治疗提供了一个有前途的途径,有可能减轻与传统治疗相关的副作用.
- 对FDP的进一步研究可能会为风湿性关节炎患者带来新的,更安全的干预措施.
- 了解RA的发病性对于开发有效的基于的治疗策略至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K


